Atlantic Central Enterprise Ltd.
ALCN
Other OTC0.00
USD
- -
- -
ISIN
BMG060551006
Return %
Stock
S&P500
1Y
0.00
26.53
3Y
100.00
76.60
5Y
100.00
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Patrick J. Rooney
- Sector
- Industrials
- Industry
- Specialty Business Services
- Address
- Cedar House Hamilton Bermuda HM 12
- IPO Date
- Sep 12, 2023
- Website
- atlanticcentral.ca
- Similar Companies
- Business
- Atlantic Central Enterprise Ltd. (ALCN) owns patents in transdermal drug delivery and skin permeation technology within the healthcare services industry. The Bermuda-based company, founded in 1992 or 1996 and headquartered at Cedar House, 41 Cedar Avenue, Hamilton HM 12, previously operated through subsidiaries providing medical services including cosmetic surgery and vision correction; it primarily conducted business in the United States and western Europe before transitioning to its current patent-holding focus in miscellaneous commercial services. The firm trades on OTCPK with a minimal market capitalization and limited recent financial reporting, showing no active analyst coverage or dividend payments. In recent years, Atlantic Central Enterprise Ltd. changed its name from Bamburgh Limited and listed on OTC markets since February 1997, reflecting a strategic shift from direct service provision to intellectual property ownership amid stagnant operational activity.